Professional
Projects

Financial Portfolio & Capital Management Case Study for GE HealthCare - Multinational Capital Budgeting Report

This project involved a comprehensive financial evaluation of a proposed manufacturing facility for CT Scanners at GE Healthcare. The analysis utilized future projections for demand, price per unit, variable cost of manufacturing, and foreign currency exchange to estimate future cash flows. Key financial models, including the Capital Asset Pricing Model (CAPM), Net Present Value (NPV), and Internal Rate of Return (IRR), were employed to assess the viability of the project.

​

The findings informed the executive decision-making process on whether to proceed with the investment. Additionally, potential risks were identified, and financial strategies were proposed to mitigate these risks and optimize the project’s outcome for GE Healthcare. 

Financial Statement Preparation and Yearly Performance Analysis for BP AMOCO 

In this project, we conducted an in-depth financial analysis of BP Amoco, assessing its performance from the onset of the COVID-19 pandemic through 2023. Our work involved a comprehensive review of the company’s financial statements to understand how it navigated the challenges posed by the pandemic. We performed ratio analysis to evaluate BP’s liquidity, profitability, and operational efficiency during this period.

​

Additionally, a terminal valuation of the firm’s free cash flow was conducted, estimating the long-term value for both the company and its common equity holders. This project demonstrated our team's expertise in financial analysis, forecasting, and valuation techniques, providing key insights into BP Amoco’s financial resilience and strategic positioning post-pandemic.

Pharma Portfolio and Drug Discovery Management: NGMBIO & MERCK - Drug Discovery of NGM621 for Geographic Atrophy

This project involved an retrospective review of NGM621, a drug developed by NGM Biopharmaceuticals in partnership with Merck, aimed at treating geographic atrophy, a progressive form of age-related macular degeneration. NGM621 was designed to inhibit complement factor C3, a key protein in the complement cascade, to slow retinal degeneration. However, the drug did not meet efficacy endpoints in its phase 2 clinical trials.

​

The analysis covered the drug's mechanism of action, its competitive landscape, including other therapies in development targeting geographic atrophy, and the financial outlook for both NGM and Merck in light of the trial’s failure. This setback presented challenges for both companies, with NGM's stock value impacted and Merck facing a strategic reevaluation of its ophthalmology pipeline. The project demonstrated the ability to integrate scientific analysis with business insights, providing a comprehensive view of market dynamics and corporate implications.